Cardiol Therapeutics

CRDL Rare disease Lead: Phase 3 4 Biotech Distilled articles ↓

Catalyst timeline

CardiolRx MAVERIC topline1Q 2027CardiolRx MAVERIC topline, 1Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

CardiolRx

cannabidiol

Small Molecule Target: inflammasome pathway, NLRP3 inflammasome

Recurrent Pericarditis Phase 3 oral NCT05494788
Acute Myocarditis Phase 2 oral NCT05180240
Heart Failure subcutaneous

CRD-38

Small Molecule

Heart Failure Preclinical subcutaneous

Biotech Distilled coverage (4)

2026-05-12 UPDATE: Cardiol Therapeutics (CRDL) - The Q1 Print Adds a “Q3 2026” Asterisk to the Enrollment Clock
2026-05-08 UPDATE: Cardiol Therapeutics (CRDL) - JAHA Validates the Pilot, Enrollment Jumps to 75% 🔒 Paid
2026-04-05 UPDATE: Cardiol Therapeutics (CRDL) - The Dilution Gap Closes as MAVERIC Approaches 🔒 Paid
2026-03-02 Cardiol Therapeutics (CRDL): Scientific Deep Dive for CardioRx and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.